Daniel DeAngelo, MD
I am involved with clinical protocols designed to treat patients with de novo or relapsed acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) as well as novel therapeutic approaches for the patient with myelodysplasia.
My current research interests include novel immunotherapeutic approaches to the treatment of acute myelogenous leukemia and myelodysplasia. I am currently developing leukemia tumor vaccines from patients with AML or advanced myelodysplasia and will be assaying for immunological and serological responses.
Dana Farber Cancer Institute: 450 Brookline Ave, Boston, MA 02215, USA